Filing Flows › Entrada Therapeutics (TRDA) › R&D spending
Entrada Therapeutics (TRDA) R&D spending by quarter
Entrada Therapeutics' R&D spending was $32.4M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 7 quarters it ranged from $32.1M (Q1 2025) to $38.4M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $32.4M | -8% | -16% |
| Q2 2026 | $35.4M | +7% | -7% |
| Q1 2026 | $33.1M | -3% | +3% |
| Q4 2025 | $34.0M | -11% | — |
| Q3 2025 | $38.4M | +1% | — |
| Q2 2025 | $37.9M | +18% | — |
| Q1 2025 | $32.1M | — | — |
Q3 2026 at a glance
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Entrada Therapeutics' R&D spending?
Entrada Therapeutics' R&D spending was $32.4M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Entrada Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $32.1M (Q1 2025) to $38.4M (Q3 2025).